These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16848691)

  • 1. Pharmacological targets in the treatment of abdominal aortic aneurysms.
    Bergoeing MP; Thompson RW; Curci JA
    Expert Opin Ther Targets; 2006 Aug; 10(4):547-59. PubMed ID: 16848691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of an effective drug therapy for abdominal aortic aneurysm.
    Golledge J; Moxon JV; Singh TP; Bown MJ; Mani K; Wanhainen A
    J Intern Med; 2020 Jul; 288(1):6-22. PubMed ID: 31278799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of abdominal aortic aneurysm.
    Miyake T; Morishita R
    Cardiovasc Res; 2009 Aug; 83(3):436-43. PubMed ID: 19454489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms.
    Sho E; Chu J; Sho M; Fernandes B; Judd D; Ganesan P; Kimura H; Dalman RL
    J Vasc Surg; 2004 Jun; 39(6):1312-21. PubMed ID: 15192574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoclastogenesis in Abdominal Aortic Aneurysms: A New Therapeutic Target.
    Leung AD; Yamanouchi D
    Curr Drug Targets; 2018; 19(11):1233-1240. PubMed ID: 28950811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms.
    Xu B; Xuan H; Iida Y; Miyata M; Dalman RL
    Curr Drug Targets; 2018; 19(11):1318-1326. PubMed ID: 29359665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of abdominal aortic aneurysms.
    Dawson J; Choke E; Sayed S; Cockerill G; Loftus I; Thompson MM
    Curr Vasc Pharmacol; 2006 Apr; 4(2):129-49. PubMed ID: 16611155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm.
    Yoshimura K; Morikage N; Nishino-Fujimoto S; Furutani A; Shirasawa B; Hamano K
    Curr Drug Targets; 2018; 19(11):1265-1275. PubMed ID: 29284386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update.
    Wang YD; Liu ZJ; Ren J; Xiang MX
    Curr Vasc Pharmacol; 2018 Jan; 16(2):114-124. PubMed ID: 28412911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role for anti-angiogenic therapy in abdominal aortic aneurysms.
    Vijaynagar B; Bown MJ; Sayers RD; Choke E
    Eur J Clin Invest; 2013 Jul; 43(7):758-65. PubMed ID: 23672465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice.
    Umebayashi R; Uchida HA; Kakio Y; Subramanian V; Daugherty A; Wada J
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):903-912. PubMed ID: 29437572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear receptors in abdominal aortic aneurysms.
    Neels JG; Hassen-Khodja R; Chinetti G
    Atherosclerosis; 2020 Mar; 297():87-95. PubMed ID: 32105947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial.
    Thompson RW; Baxter BT
    Ann N Y Acad Sci; 1999 Jun; 878():159-78. PubMed ID: 10415728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of tetracycline derivatives to suppress the growth of abdominal aortic aneurysms.
    Thompson RW; Liao S; Curci JA
    Adv Dent Res; 1998 Nov; 12(2):159-65. PubMed ID: 9972142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms.
    VAN KUIJK JP; FLU WJ; WITTEVEEN OP; VOUTE M; BAX JJ; POLDERMANS D
    J Cardiovasc Surg (Torino); 2009 Oct; 50(5):599-609. PubMed ID: 19741575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Turning back the clock: regression of abdominal aortic aneurysms via pharmacotherapy.
    Aoki H; Yoshimura K; Matsuzaki M
    J Mol Med (Berl); 2007 Oct; 85(10):1077-88. PubMed ID: 17522832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Theories and Clinical Trial Evidence for Limiting Human Abdominal Aortic Aneurysm Growth.
    Yu J; Liu S; Huang J; Wang W
    Curr Drug Targets; 2018; 19(11):1302-1308. PubMed ID: 29141546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fucoidan attenuates angiotensin II-induced abdominal aortic aneurysms through the inhibition of c-Jun N-terminal kinase and nuclear factor κB activation.
    Tsai SH; Wang JC; Liao WI; Hsu YJ; Lin CY; Liao MT; Huang PH; Lin SJ
    J Vasc Surg; 2018 Dec; 68(6S):72S-81S.e1. PubMed ID: 29290496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory cell phenotypes in AAAs: their role and potential as targets for therapy.
    Dale MA; Ruhlman MK; Baxter BT
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1746-55. PubMed ID: 26044582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening aortic drug treatments through arterial compliance measurements.
    Rentschler ME; Baxter BT
    Curr Vasc Pharmacol; 2008 Oct; 6(4):250-7. PubMed ID: 18855713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.